Session » Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

Date: Monday, October 22, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1607

Achievement of Cdapsa Low Disease Activity or Remission Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psa in Subjects Treated with Apremilast

9:00AM-11:00AM: Abstract Number: 1655

Achieving Remission in Psoriatic Arthritis By Early Initiation of TNF Inhibition: A Double-Blind, Randomized, Placebo-Controlled Trial of Golimumab + Methotrexate Versus Placebo + Methotrexate

9:00AM-11:00AM: Abstract Number: 1618

Adipose Tissue Inflammation in Psoriatic Arthritis: Overexpression of a Wide Array of Inflammatory Mediators and Associations with Disease and Treatment Characteristics

9:00AM-11:00AM: Abstract Number: 1622

ASAS Consensus on Spanish Nomenclature for Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1627

Assessment of Myocardial Dysfunction Using Speckle Tracking Echocardiography in Patients with Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1625

Association of HLA-B Type and Sacroiliitis in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1596

Atherosclerotic Cardiovascular Disease in Psoriatic Arthritis: Evaluation of Risk Factor Management and Use of Aspirin and Statin for Prevention in a Primary Care Setting

9:00AM-11:00AM: Abstract Number: 1597

Bone Mineral Density and Serum Biomarkers of Bone Turnover in Ankylosing Spondylitis Patients Treated with Secukinumab: 2-Year Data from the Pivotal Phase 3 Study

9:00AM-11:00AM: Abstract Number: 1589

Cardiac Biomarkers and Carotid Atherosclerosis and Its Progression in Psoriatic Disease

9:00AM-11:00AM: Abstract Number: 1645

Clinical Features of Axial Spondyloarthritis Patients Diagnosed in Secondary Versus a Tertiary Hospital

9:00AM-11:00AM: Abstract Number: 1649

Cohort Identification of Axial Spondyloarthritis in a Large Healthcare Dataset: Current and Future Methods

9:00AM-11:00AM: Abstract Number: 1615

Comparative Risk of Atrial Fibrillation and Cardiovascular Events between TNF-Inhibitors and Ustekinumab in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study

9:00AM-11:00AM: Abstract Number: 1613

Dactylitis in Early Spondyloarthritis. Baseline Data from a Prospective French National Cohort

9:00AM-11:00AM: Abstract Number: 1598

Depression and Anxiety Reduce Probability of Achieving a State of Minimal Disease Activity in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1660

Depression Has a Greater Impact on Psoriatic Arthritis Than Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1602

Disease Characteristics, Quality of Life, and Work Productivity By Enthesitis Sites: Real-World Data from the US Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

9:00AM-11:00AM: Abstract Number: 1630

Do Symptoms of Depression and Anxiety Influence Treatment Response and Long-Term Physical Health Outcomes in Ankylosing Spondylitis?

9:00AM-11:00AM: Abstract Number: 1651

Epidemiology of Depression and Anxiety in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 1593

Extra-Articular Manifestations, Neoplasms and Cardiovascular Events in a Series of Spondyloarthritis from a Single Center

9:00AM-11:00AM: Abstract Number: 1661

Factors That May be Associated with Uveitis in Patients with Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1633

Fragility Fractures in Psoriatic Arthritis Patients: A Matched-Control Study

9:00AM-11:00AM: Abstract Number: 1592

Frequency and Pattern of the Uveitis in Spondyloarthritis with Biological Therapy

9:00AM-11:00AM: Abstract Number: 1636

Frequency and Specificity of MRI Lesions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis and Non-Specific Back Pain: First Analysis of MRI Scans from the Assessments in Spondyloarthritis International Society Classification Cohort

9:00AM-11:00AM: Abstract Number: 1603

Gender-Specific Differences in Chinese Patients with Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 1621

Higher Serum Uric Acid Levels Protect Against Osteoporosis in Patients with Axial Spondyloarthropathy

9:00AM-11:00AM: Abstract Number: 1611

Hospitalizations for Serious Infections in Psoriatic Arthritis Patients: Data from the National Inpatient Sample 2000-2014

9:00AM-11:00AM: Abstract Number: 1629

Hyperlipoproteinemia (a) in Patients with Spondyloarthritis. Results of the CARMA Study

9:00AM-11:00AM: Abstract Number: 1601

Impact of Clinical Specialty Setting and Geographic Regions on Disease Management in Patients with Psoriatic Arthritis: Results from a Cross-Sectional Observational Study in the United States

9:00AM-11:00AM: Abstract Number: 1638

Impact of Extra-Articular Manifestations on Patient-Reported Outcomes in Ankylosing Spondylitis and Psoriatic Arthritis: Interim Results from the Complete Studies

9:00AM-11:00AM: Abstract Number: 1604

Impact of Time to Minimal Disease Activity and Quality of Life One Year after Diagnosis of Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1644

Improvement in Morning Stiffness in Subjects with Psa Is Associated with Improvements in Pain, Physical Function, and Patient Global Response to Treatment

9:00AM-11:00AM: Abstract Number: 1654

Improvement of Cytological Grade and Tear Production in Ankylosing Spondylitis Patients Under Anti-TNF Therapy: A Long-Term Follow-up

9:00AM-11:00AM: Abstract Number: 1631

Incidence of Uveitis in Patients with Spondyloarthritis: The Impact of Biologics Era.a Multicenter Study Using Data from International ASAS-Comospa Study

9:00AM-11:00AM: Abstract Number: 1610

Incremental Benefits to Quality of Life Associated with Achieving Higher Levels of American College of Rheumatology Response and Skin Clearance in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1617

Influence of Disease Activity in the Physical Activity of Psoriatic Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1623

Insight into the Quality of Life of Patients with Ankylosing Spondylitis: Real-World Data from a US-Based Life Impact Survey

9:00AM-11:00AM: Abstract Number: 1662

Interplay Among Inflammation, Adipokines and Endothelial Dysfunction in Patients with Psoriatic Arthritis. Relationship with Cardiovascular and Metabolic Comorbidities. Modulation By Apremilast

9:00AM-11:00AM: Abstract Number: 1656

Is a Positive Family History of Spondyloarthritis Relevant for Diagnosing Axial Spondyloarthritis Once HLA-B27 Status Is Known? Data from the ASAS, DESIR, and SPACE Cohorts

9:00AM-11:00AM: Abstract Number: 1628

Is Axial Psoriatic Arthritis Distinct from Ankylosing Spondylitis with and without Concomitant Psoriasis?

9:00AM-11:00AM: Abstract Number: 1591

Is Enthesitis a Marker of Disease Severity in Early Psoriatic Arthritis?

9:00AM-11:00AM: Abstract Number: 1620

Lateral DXA More Effective in Detecting Osteoporosis Than Conventional DXA in Axial Spondyloarthropathy

9:00AM-11:00AM: Abstract Number: 1594

Liver Enzyme Elevation in Patients with Ankylosing Spondylitis Treated with TNF Inhibitor: A Single-Center Historical Cohort Study

9:00AM-11:00AM: Abstract Number: 1595

Malignancy in Psoriatic Disease

9:00AM-11:00AM: Abstract Number: 1590

Metabolomics Profile Predicts Carotid Atherosclerosis Progression in Psoriatic Disease

9:00AM-11:00AM: Abstract Number: 1652

Musculoskeletal Involvement in Inflammatory Bowel Disease’S Patients: A Mono Centric Experience

9:00AM-11:00AM: Abstract Number: 1612

Myocardial Infarctions Among Ankylosing Spondylitis Patients in a Large US Insurance Database

9:00AM-11:00AM: Abstract Number: 1619

Patterns and Outcomes on As Patients Disease Activity Using Smart System of Disease Management (SSDM): Analysis of T2T Pattern Shift and the Correlation between Disease Activity and Mental Health

9:00AM-11:00AM: Abstract Number: 1599

Performance of Referral Strategies for Spondyloarthritis: A Population-Based Nationwide Study

9:00AM-11:00AM: Abstract Number: 1605

Prevalence of Anterior Uveitis in Patients with Spondyloarthropathy in a Single US Academic Center: A Retrospective Study from Routine Care

9:00AM-11:00AM: Abstract Number: 1614

Prevalence of Sonographic Enthesitis in Patients with Psoriasis without Arthritis and Its Association Risk Factors of Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1646

Prevalence of Spondyloarthritis in Patients with Anterior Uveitis

9:00AM-11:00AM: Abstract Number: 1643

Psa Impact of Disease Questionnaire Scores Are Correlated with Disease Activity, As Measured By Cdapsa in Patients with Psa

9:00AM-11:00AM: Abstract Number: 1653

Psychological Distress in Patients with Axial Spondyloarthritis in Europe. Results from the European Map of Axial Spondyloarthritis Survey

9:00AM-11:00AM: Abstract Number: 1600

Psychometric Properties of the Assessment of Spa International Society Health Index in Patients with Active As/Radiographic Axial Spa in a Phase 3 Clinical Study

9:00AM-11:00AM: Abstract Number: 1624

Real-World Insight into the Disease Burden and Treatment of Spondyloarthritis from a US-Based Life Impact Survey

9:00AM-11:00AM: Abstract Number: 1616

Region-Specific Differences in Clinical Presentation of Patients with Axial Spondyloarthritis – Results from a Large Multinational Cohort Study

9:00AM-11:00AM: Abstract Number: 1588

Risk of Cancer in Patients with Psoriasis/Psoriatic Arthritis: A Population-Based Study in the Province of British Columbia

9:00AM-11:00AM: Abstract Number: 1637

Serious Infections Among Psoriatic Arthritis Patients Taking TNF Inhibitors Versus Non-TNF Biologics: A Systematic Review and Network Meta-Analysis

9:00AM-11:00AM: Abstract Number: 1648

Smoking Status in Patients with Psoriasis and Psoriatic Arthritis: An Irish Perspective

9:00AM-11:00AM: Abstract Number: 1641

Spa-Net: A Disease-Specific Integrated Ehealth System and Quality Registry for Spondyloarthritis in Daily Practice in the Netherlands

9:00AM-11:00AM: Abstract Number: 1650

Subclinical Atheromatosis and Estimation of Cardiovascular Risk in Patients with Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1659

Sustained Improvements in Physical Function, Quality of Life, and Work Productivity after Ixekizumab Therapy in Patients with Active Psoriatic Arthritis: 3-Year Results

9:00AM-11:00AM: Abstract Number: 1642

Systematic Screening of Comorbidities Improves Vaccination Rates, Skin Cancer Screening and Vitamin D Supplementation in Patients with Axial Spondyloarthritis: Results of a Prospective, Controlled ,One Year Randomised Trial

9:00AM-11:00AM: Abstract Number: 1606

The 66/68 Joint Count for the Measurement of MSK Disease Activity/Peripheral Joint Activity in Psa: A Grappa-Omeract Working Group Initiative

9:00AM-11:00AM: Abstract Number: 1626

The Disease Expression in Familial and Sporadic Axial Spondyloarthritis Patients

9:00AM-11:00AM: Abstract Number: 1657

The Effect of Guselkumab on Enthesitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1634

The Impact of Comorbidities on Physical Function in Patients with Ankylosing Spondylitis and Psoriatic Arthritis Attending Rheumatology Clinics. Results of a National Study

9:00AM-11:00AM: Abstract Number: 1609

The Incidence Rate of Spondyloarthritis in Slovenia

9:00AM-11:00AM: Abstract Number: 1608

The Value of Carotid Ultrasound in Cardiovascular Risk Stratification in Patients with Psoriatic Disease

9:00AM-11:00AM: Abstract Number: 1632

Ultrasonographic Evaluation of the Enthesis in Patients Affected By Entheropatic Spondiloarthritis. Focus on Distal Enthesis of the Patellar Tendon

9:00AM-11:00AM: Abstract Number: 1639

Uveitis As First Symptom in Patients with Spondyloarthritis. Data from the Spanish Registry Regisponser

9:00AM-11:00AM: Abstract Number: 1647

Uveitis, the Most Faithful Partner of Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1635

Validity of Patient-Reported Outcomes Measurement Information System Measures in Ankylosing Spondylitis Patients

9:00AM-11:00AM: Abstract Number: 1658

Which Factors Influence the Diagnostic Delay in Patients with Axial Spondyloarthritis?

9:00AM-11:00AM: Abstract Number: 1640

Work Disability in Psoriatic Arthritis Patients

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].